MOTS-C
Mitochondrial-Derived Peptide
Also known as: MOTS-c, MOTSc, Mitochondrial Open Reading Frame of the 12S rRNA-c
Last updated May 4, 2026
What is MOTS-C?
If you’ve heard MOTS-C described as “the exercise mimetic peptide” and want to know what’s actually behind that claim, here’s the honest version.
MOTS-C is a 16-amino-acid peptide encoded inside your mitochondria — the energy-producing organelles in your cells. It was discovered in 2015 and is one of a small class of “mitochondrial-derived peptides” that researchers have only started characterizing in the last decade.
What it does: when your cells are under metabolic stress — exercise, fasting, calorie restriction — your mitochondria release MOTS-C into the bloodstream. Once there, it activates a pathway called AMPK (AMP-activated protein kinase), your body’s central “energy sensor.” AMPK activation tells cells to burn fuel more efficiently, become more sensitive to insulin and resist storing excess energy as fat. In other words, MOTS-C effectively mimics some of the metabolic signaling that exercise produces naturally.
MOTS-C blood levels also decline with age, which has fueled “longevity peptide” marketing — but the actual evidence sits in metabolic markers, not longevity outcomes. We get into what the research does and doesn’t show below.
What Does the Research Actually Show?
This is the strongest part of MOTS-C’s evidence base. In animal models — primarily mice fed high-fat diets — MOTS-C improves insulin sensitivity, reduces fat mass and prevents diet-induced obesity. The effect is mechanistically clear: AMPK activation drives glucose uptake into muscle and reduces fat storage. Multiple research groups have replicated these findings. Human data is thin but exists. Small clinical studies in adults with insulin resistance or prediabetes have shown improved glucose tolerance and metabolic markers after MOTS-C administration over 8–12 weeks. Sample sizes have been under 30 subjects per study; none are placebo-controlled at the scale needed for definitive evidence.
Animal studies show MOTS-C-treated mice run longer on treadmills and show improved muscle metabolic function. The mechanism is plausible — AMPK activation is part of how exercise produces fitness adaptations. Human exercise capacity data is essentially absent. Practitioner reports suggest improved workout recovery and endurance, but no controlled trials have measured this in athletes or recreationally active adults.
It’s worth noting: without controlled human trials at scale, we can’t rule out that practitioner-reported benefits reflect placebo, lifestyle changes accompanying the protocol or normal individual variation. The mechanistic case for MOTS-C is among the better-established for any T2 compound — but a strong mechanism doesn’t replace controlled human evidence.
How Is MOTS-C Administered?
| Route | Subcutaneous injection |
| Dosage range | 5–10 mg per dose |
| Frequency | 2–3x weekly |
| Protocol | Cycled or continuous use; cycle protocols vary widely between providers |
| Access | Provider-prescribed; gray-market access common — see Is It Legal? section below |
For phase-by-phase response timing and biomarker tracking, see our What to Expect on MOTS-C →
What Are the Side Effects and Risks?
- Injection site reactions (mild, transient).
- Headache (uncommon).
- Mild fatigue or flu-like symptoms during initial doses (uncommon).
- Possible blood glucose changes — monitoring is recommended for diabetics.
- Pregnancy and breastfeeding are absolute contraindications.
Who Should NOT Use MOTS-C?
If you are diabetic on insulin or sulfonylureas: MOTS-C improves insulin sensitivity. That’s the desired effect — but if you’re already on glucose-lowering medication, the combined effect can drive blood sugar too low. Hypoglycemia is a real risk in this scenario. Your prescribing physician for diabetes care must be in the loop, and dose adjustments to your existing medications may be needed.
If you are pregnant or breastfeeding: No safety data exists. This is not a situation where “probably fine” is an acceptable standard.
If you have an active malignancy or recent cancer history: AMPK activation has complex effects on cancer biology — protective in some contexts, potentially supportive of tumor growth in others, depending on cancer type. The interaction is not well characterized in humans on MOTS-C. If you have an active cancer, are in remission or have a strong family history, this conversation belongs with your oncologist before your peptide provider.
If you are a competitive athlete in a tested sport: MOTS-C is not currently on WADA’s prohibited list, but the regulatory landscape for performance-enhancing peptides shifts frequently. Verify current status with your governing body before starting. “It wasn’t banned when I started” has not historically been a successful defense in anti-doping cases.
The lag in CRP response is worth understanding before drawing conclusions from a single result.
Before You Start: Get Baseline Labs
We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include CBC, CMP, fasting glucose, fasting insulin, HbA1c (3-month blood sugar average) and a full lipid panel. If you have existing metabolic concerns, also consider HOMA-IR (insulin resistance index) and a body composition measurement (DEXA or bioimpedance).
Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.
Order at-home labs from Everlywell →Lab recommendations are the same regardless of which service you use.
What You'll Need
If your provider prescribes an injectable protocol, you'll need basic supplies.
- Bacteriostatic Water (30ml)Link coming soon
- Insulin Syringes 29 gauge (100ct)Link coming soon
- Alcohol Prep Pads (200ct)Link coming soon
- Sharps ContainerLink coming soon
Supply links are affiliate links. We may earn a commission at no cost to you. We only link to commodity supplies, never to peptide products.
- 1Based on my specific metabolic situation, is MOTS-C an appropriate addition to my plan, or should we focus on diet, exercise and established interventions first?
- 2If I’m currently on diabetes medication, what monitoring or dose adjustments will I need while on MOTS-C?
- 3What’s the current compounding availability for MOTS-C given the post-Category 2 / pre-PCAC limbo? On what legal basis is your pharmacy filling these prescriptions?
- 4What baseline labs do you want me to complete? How will we measure response — by symptoms, by lab markers or both?
- 5Which compounding pharmacy do you use, and is it 503A or 503B?
- 6What does success look like at 8 weeks, and at what point would we conclude MOTS-C isn’t working?
- 7How should I think about MOTS-C in the context of lifestyle changes — is your protocol designed around it complementing diet and exercise, or replacing them?
Is MOTS-C Legal in 2026?
Not FDA-approved. Removed from Category 2 effective April 22, 2026. PCAC review scheduled for July 23, 2026 — MOTS-C is on the agenda alongside BPC-157, KPV, and TB-500. Compounding cannot resume until after PCAC review and a final FDA determination adds MOTS-C to the 503A bulks list. If approved, it will be available via prescription through licensed compounding pharmacies — it will NOT be available over the counter or FDA-approved.
The FDA accepts public comments through Docket FDA-2025-N-6895. Comments received by July 9, 2026 will be provided to the committee.
How Do I Get MOTS-C Through a Legitimate Provider?
No verified providers currently meet our evaluation criteria for this compound. Subscribe to be notified when that changes.
When provider links go live, we’ll disclose all affiliate relationships here.